Proton therapy treatment among prostate cancer patients has shown overall good survival rates and fewer complications when compared to commonly used Intensity-Modulated Radiation Therapy treatment.
This new study was presented at the 4th Annual Particle Therapy Co-Operative Group North-America (PTCOG-NA) Conference on in Chicago.
Proton Beam Therapy for Cancer Treatment
Proton therapy is a form of radiotherapy for cancer treatment which uses a proton beam that is targeted precisely on the tumor cells, destroying them with minimal damage to surrounding healthy tissue. Proton therapy can treat various types of cancer.
Advertisement
‘The five-year survival rate with proton therapy in prostate cancer patients has shown a good 93.25% results, when compared to 88.43% score with Intensity-Modulated Radiation Therapy for treatment
’
Tweet it Now
"This new evidence supports that proton therapy is at least as good as standard radiation therapy and may be significantly better in some areas, especially protecting normal tissue outside of the prostate," said the study's lead author William Hartsell, MD, medical director of the Northwestern Medicine Chicago Proton Center.
"In addition, the evidence shows that proton therapy is advantageous for younger patients who we are most concerned about developing secondary cancers later in life."
![Advanced Proton Therapy Shows Promise To Treat Lung Cancer Recurrence]( "Advanced Proton Therapy Shows Promise To Treat Lung Cancer Recurrence")
More than 222,500 people will be diagnosed and 155,870 will die from lung cancer in 2017, with recurrence the primary cause of death in these patients.
Proton therapy uses protons - heavy, positively charged atomic particles - instead of the standard X-rays used in conventional radiation therapy. Protons deposit much of their energy, or dose, directly in the tumor and then stop, whereas conventional radiation continues to deposit the dose beyond the tumor.
Dr. Hartsell and colleagues reviewed the records of over 28,000 Intensity-Modulated Radiation Therapy (IMRT) patients and 851 proton patients who received treatment from 2006-2012, using the Medicare and SEER (Surveillance, Epidemiology, and End-Results Reporting) national databases.
The proton patients were matched to Intensity-Modulated Radiation Therapy (IMRT) patients in a 1:5 matching process using several parameters, including comorbidity index, cancer stage, tumor grade, adjuvant chemo/hormone therapy, age, zip code and ethnicity.
Using the matched patient cohort, the 5-year overall survival rate for proton therapy was 93.25% compared to 88.43% for IMRT. For the matched group of intermediate-risk patients, the gap was slightly greater with a 5-year overall survival for proton therapy patients of 93.65% compared to 88.27% for IMRT.
The study also reviewed the incidence of complications and found significantly more in patients with bladder, endocrine or "other" complications with to Intensity-Modulated Radiation Therapy (IMRT) compared to protons.
In addition, there were greater numbers of patients with secondary malignancies with Intensity-Modulated Radiation Therapy (IMRT). 10.5% for IMRT compared to 6.1% for proton therapy at five years.
"This study is a significant update on the efficacy of proton therapy for prostate cancer. Many insurance companies are relying on outdated and incorrect data to determine coverage," said Dr. Hartsell.
Source: Eurekalert
Advanced Proton Therapy Shows Promise To Treat Lung Cancer Recurrence
More than 222,500 people will be diagnosed and 155,870 will die from lung cancer in 2017, with recurrence the primary cause of death in these patients.
Advertisement
Proton therapy uses protons - heavy, positively charged atomic particles - instead of the standard X-rays used in conventional radiation therapy. Protons deposit much of their energy, or dose, directly in the tumor and then stop, whereas conventional radiation continues to deposit the dose beyond the tumor.
Dr. Hartsell and colleagues reviewed the records of over 28,000 Intensity-Modulated Radiation Therapy (IMRT) patients and 851 proton patients who received treatment from 2006-2012, using the Medicare and SEER (Surveillance, Epidemiology, and End-Results Reporting) national databases.
The proton patients were matched to Intensity-Modulated Radiation Therapy (IMRT) patients in a 1:5 matching process using several parameters, including comorbidity index, cancer stage, tumor grade, adjuvant chemo/hormone therapy, age, zip code and ethnicity.
Using the matched patient cohort, the 5-year overall survival rate for proton therapy was 93.25% compared to 88.43% for IMRT. For the matched group of intermediate-risk patients, the gap was slightly greater with a 5-year overall survival for proton therapy patients of 93.65% compared to 88.27% for IMRT.
The study also reviewed the incidence of complications and found significantly more in patients with bladder, endocrine or "other" complications with to Intensity-Modulated Radiation Therapy (IMRT) compared to protons.
In addition, there were greater numbers of patients with secondary malignancies with Intensity-Modulated Radiation Therapy (IMRT). 10.5% for IMRT compared to 6.1% for proton therapy at five years.
"This study is a significant update on the efficacy of proton therapy for prostate cancer. Many insurance companies are relying on outdated and incorrect data to determine coverage," said Dr. Hartsell.
Source: Eurekalert
Proton Beam Therapy Safe and Effective in Pediatric Head and Neck Cancers
Protons may be an important tool in improving quality of life both during treatment and for years after for pediatric patients with head and neck cancer.
Advertisement
 Varian ProBeam Proton Therapy System Gets Approval in EuropeThe ProBeam proton therapy system with Dynamic Peak scanning helps doctors deliver the dose precisely to minimize dose to healthy tissue. | Advertisement
|
Advertisement
Recommended Readings
Latest Menīs Health News
Prostate cancer mutations targeting PI3K signaling are greatly influenced by PLEKHS1, a protein, enhances cancer drug therapy efficiency.
A substantial reduction in mortality risk was found in older men taking medications for lower urinary tract symptoms (LUTS).
Men's human papillomavirus (HPV) infections underscore the importance of their participation in efforts to reduce HPV-related diseases in all genders.
Men who received active Optilume treatment demonstrated more significant improvement in symptoms related to benign prostatic hyperplasia.
Investigation of sperm formation and its molecular intricacies reveals a potential connection between infertility and alterations in sperm amino acids.
